24 February 2018
News and Views
Links and Services
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment, reports the most recent issue of the Alimentary Pharmacology & Therapeutics.
Therapies that maintain remission for patients with Crohn's disease are essential. Stable remissi
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors